Key result
Treatment with an rAAV6-microdystrophin vector halted progressive disease activity in mdx reporter mice, demonstrating the utility of bioluminescence imaging for noninvasive monitoring of muscular dystrophy therapies.
Why the study?
Does rAAV-6 microdystrophin gene therapy halt muscle degeneration in the mdx mouse model of DMD as monitored by noninvasive bioluminescence imaging?
Does rAAV-6 microdystrophin gene therapy halt muscle degeneration in the mdx mouse model of DMD as monitored by noninvasive bioluminescence imaging?
A novel bioluminescence imaging reporter mouse model successfully and noninvasively monitors muscle degeneration and response to rAAV-microdystrophin gene therapy in Duchenne muscular dystrophy.
Answers are grounded in this paper and cite their sources.
Supports preclinical microdystrophin development in DMD models; leaves open translation to patients pending clinical trials.
model of DMD. The reporter mice, which we term the dystrophic Degeneration Reporter strains, contain an inducible CRE-responsive luciferase reporter active in mature myofibers. In these mice, muscle degeneration is reflected in changes in the level of luciferase expression, which can be monitored using noninvasive, bioluminescence imaging. We monitored the natural history and disease progression in these dystrophic report mice and found that decreases in luciferase signals directly correlated with muscle degeneration. We further demonstrated that this reporter strain, as well as a previously reported Regeneration Reporter strain, successfully reveals the effectiveness of a gene therapy treatment following systemic administration of a recombinant adeno-associated virus-6 (rAAV-6) encoding a microdystrophin construct. Our data demonstrate the value of these noninvasive imaging modalities for monitoring disease progression and response to therapy in mouse models of muscular dystrophy.
No takes yet. Share an insight, caveat, or question.
Filareto et al. (2018) studied Duchenne muscular dystrophy (mdx mouse model). rAAV6-microdystrophin vs. Saline was evaluated on Bioluminescence imaging (BLI) signal reflecting muscle degeneration/regeneration (p=<0.0001). Treatment with an rAAV6-microdystrophin vector halted progressive disease activity in mdx reporter mice, demonstrating the utility of bioluminescence imaging for noninvasive monitoring of muscular dystrophy therapies.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: